Table of Contents
Molecular Biology International
Volume 2012, Article ID 701814, 8 pages
http://dx.doi.org/10.1155/2012/701814
Research Article

Combined RASSF1A and RASSF2A Promoter Methylation Analysis as Diagnostic Biomarker for Bladder Cancer

1Department of Radiation Oncology, The Ohio State University, Columbus, OH 43210, USA
2Department of Urology, The Ohio State University, Columbus, OH 43210, USA

Received 1 November 2011; Accepted 29 December 2011

Academic Editor: Farida Latif

Copyright © 2012 Wei Meng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. R. Serizawa, U. Ralfkiær, K. Steven et al., “Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events,” International Journal of Cancer, vol. 129, no. 1, pp. 78–87, 2011. View at Publisher · View at Google Scholar
  2. Y. K. Bae, A. Brown, E. Garrett et al., “Hypermethylation in histologically distinct classes of breast cancer,” Clinical Cancer Research, vol. 10, no. 18 I, pp. 5998–6005, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Li, Z. Zhang, Z. Dait et al., “RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer,” Neoplasia, vol. 5, no. 4, pp. 362–366, 2003. View at Google Scholar · View at Scopus
  4. Y. Wang, Z. Yu, T. Wang, J. Zhang, L. Hong, and L. Chen, “Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer,” Lung Cancer, vol. 56, no. 2, pp. 289–294, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. H. A. Ghazaleh, R. S. Chow, S. L. Choo et al., “14-3-3 mediated regulation of the tumor suppressor protein, RASSF1A,” Apoptosis, vol. 15, no. 2, pp. 117–127, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Shivakumar, J. Minna, T. Sakamaki, R. Pestell, and M. A. White, “The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation,” Molecular and Cellular Biology, vol. 22, no. 12, pp. 4309–4318, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Dallol, A. Agathanggelou, S. L. Fenton et al., “RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics,” Cancer Research, vol. 64, no. 12, pp. 4112–4116, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Agathanggelou, S. Honorio, D. P. Macartney et al., “Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours,” Oncogene, vol. 20, no. 12, pp. 1509–1518, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. M. D. Vos, C. A. Ellis, C. Elam, A. S. Ülkü, B. J. Taylor, and G. J. Clark, “RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor,” Journal of Biological Chemistry, vol. 278, no. 30, pp. 28045–28051, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Hesson, I. Bièche, D. Krex et al., “Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas,” Oncogene, vol. 23, no. 13, pp. 2408–2419, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Eckfeld, L. Hesson, M. D. Vos, I. Bieche, F. Latif, and G. J. Clark, “RASSF4/AD037 is a potential Ras effector/tumor suppressor of the RASSF family,” Cancer Research, vol. 64, no. 23, pp. 8688–8693, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. D. F. Calvisi, H. Donninger, M. D. Vos et al., “NORE1A tumor suppressor candidate modulates p21CIP1 via p53,” Cancer Research, vol. 69, no. 11, pp. 4629–4637, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Geli, P. Kogner, F. Lanner et al., “Assessment of NORE1A as a putative tumor suppressor in human neuroblastoma,” International Journal of Cancer, vol. 123, no. 2, pp. 389–394, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. C. K. Lee, J. H. Lee, M. G. Lee et al., “Epigenetic inactivation of the NORE1 gene correlates with malignant progression of colorectal tumors,” BMC Cancer, vol. 10, article 577, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Buckingham, L. P. Faber, A. Kim et al., “PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients,” International Journal of Cancer, vol. 126, no. 7, pp. 1630–1639, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. N. P. C. Allen, H. Donninger, M. D. Vos et al., “RASSF6 is a novel member of the RASSF family of tumor suppressors,” Oncogene, vol. 26, no. 42, pp. 6203–6211, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. L. B. Hesson, T. L. Dunwell, W. N. Cooper et al., “The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias,” Molecular Cancer, vol. 8, article 42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. T. K. Wojdacz, A. Dobrovic, and L. L. Hansen, “Methylation-sensitive high-resolution melting,” Nature protocols, vol. 3, no. 12, pp. 1903–1908, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. C. T. Wittwer, G. H. Reed, C. N. Gundry, J. G. Vandersteen, and R. J. Pryor, “High-resolution genotyping by amplicon melting analysis using LCGreen,” Clinical Chemistry, vol. 49, no. 6, pp. 853–860, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. R. H. A. M. Vossen, E. Aten, A. Roos, and J. T. Den Dunnen, “High-resolution melting analysis (HRMA)—more than just sequence variant screening,” Human Mutation, vol. 30, no. 6, pp. 860–866, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. T. K. Wojdacz and A. Dobrovic, “Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation,” Nucleic Acids Research, vol. 35, no. 6, article e41, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Peters, K. Rehmet, N. Wilke et al., “RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis,” Molecular Cancer, vol. 6, article 49, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Honorio, A. Agathanggelou, M. Schuermann et al., “Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients,” Oncogene, vol. 22, no. 1, pp. 147–150, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. Zhang, D. Sun, N. V. Do, A. Tang, L. Hu, and G. Huang, “Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma,” International Journal of Cancer, vol. 120, no. 1, pp. 32–38, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. L. van der Weyden and D. J. Adams, “The Ras-association domain family (RASSF) members and their role in human tumourigenesis,” Biochimica et Biophysica Acta, vol. 1776, no. 1, pp. 58–85, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. M. W. Y. Chan, L. W. Chan, N. L. S. Tang et al., “Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients,” International Journal of Cancer, vol. 104, no. 5, pp. 611–616, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Yu, T. Zhu, Z. Wang et al., “A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer,” Clinical Cancer Research, vol. 13, no. 24, pp. 7296–7304, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. T. C. Zuiverloon, W. Beukers, K. A. van der Keur et al., “A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine,” British Journal of Urology International, vol. 109, no. 6, pp. 941–948, 2012. View at Publisher · View at Google Scholar
  29. C. J. Marsit, E. A. Houseman, B. C. Christensen et al., “Identification of methylated genes associated with aggressive bladder cancer,” PLoS ONE, vol. 5, no. 8, article e12334, 2010. View at Publisher · View at Google Scholar · View at Scopus